Walleye Capital
AXSM icon

Walleye Capital’s Axsome Therapeutics AXSM Stock Holding History

Walleye Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.94M Sell
35,119
-24,981
-42% -$4.31M 0.02% 701
2025
Q4 		$11M Buy
60,100
+59,600
+11,920% +$8.32M 0.03% 595
2025
Q3 		$60.7K Sell
500
-1,783
-78% -$201K ﹤0.01% 3930
2025
Q2 		$238K Buy
2,283
+697
+44% +$73.8K ﹤0.01% 3224
2025
Q1 		$185K Sell
1,586
-377
-19% -$43K ﹤0.01% 3322
2024
Q4 		$166K Sell
1,963
-44,775
-96% -$4.12M ﹤0.01% 3874
2024
Q3 		$4.2M Sell
46,738
-29,285
-39% -$2.56M 0.01% 1309
2024
Q2 		$6.12M Sell
76,023
-21,097
-22% -$1.56M 0.01% 1143
2024
Q1 		$7.75M Buy
+97,120
New +$8.15M 0.01% 996
2023
Q3 		– Sell
-86,280
Closed -$6.45M – 4857
2023
Q2 		$6.2M Buy
+86,280
New +$6.36M 0.02% 616
2022
Q2 		– Sell
-8,295
Closed -$343K – 2354
2022
Q1 		$343K Buy
+8,295
New +$257K 0.01% 1228
2020
Q1 		– Sell
-170,268
Closed -$17.6M – 942
2019
Q4 		$17.6M Buy
+170,268
New +$6.88M 1.14% 2
2018
Q3 		$62K Buy
+17,838
New +$52.9K 0.03% 276

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Walleye Capital's AXSM Position: Q1 2026 in Review

Walleye Capital reduced its Axsome Therapeutics (AXSM) stake by 42% in Q1 2026, selling an estimated $4.31M and leaving 35,119 shares worth $5.94M. The position accounts for 0.02% of the portfolio, ranked #701.

Walleye Capital first reported a position in AXSM in Q3 2018 and has held it in 13 quarters since. The position peaked at $17.6M in Q4 2019. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Walleye Capital held 35,119 shares of Axsome Therapeutics worth $5.94M as of Q1 2026.
  • Walleye Capital sold 24,981 Axsome Therapeutics shares in Q1 2026, an estimated $4.31M.
  • Axsome Therapeutics made up 0.02% of Walleye Capital's portfolio in Q1 2026, its #701 holding.
  • Walleye Capital first reported a position in Axsome Therapeutics in Q3 2018 and has held it in 13 quarters since.
  • Walleye Capital's Axsome Therapeutics position peaked at $17.6M in Q4 2019.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.